Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Liposome in Combination With Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer: Phase II Clinical Study

NCT06578052 is registered in ClinicalTrials.gov with Junjie Hang as lead sponsor.

NCT NCT06578052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06578052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Liposome in Combination With Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer: Phase II Clinical Study
Lead sponsor
Junjie Hang
Phase
Not applicable
Overall status
Recruiting
Start date
August 28, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer